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Summary The expression of basic fibroblast growth factor (bFGF) and two of its receptors, FGFR1 and
FGFR2, was detected using the polymerase chain reaction, and quantified by comparison to the relative
amount of product obtained following co-amplification of the ubiquitous glyceraldehyde phosphate dehydro-
genase transcript. Varying levels were found in the vast majority of both cancer and non-malignant breast
biopsies as well as in samples of several other normal human tissues. Significantly less bFGF was present in
cancers (P< 0.0001). Similarly, FGFR2 product was also much less in cancer tissues (P = 0.0078), as was
FGFR1 (P = 0.002). FGFR1 levels in cancers tended to be higher in those which were oestrogen receptor
positive (P<0.06). Amplification of different coding regions showed evidence of variant forms of FGFR1
RNA. Cancers appeared to have a significantly greater proportion of PCR product corresponding to the
region between the third immunoglobulin like domain and the tyrosine kinase domain (P = 0.046). Differential
expression was observed in breast cell lines, with bFGF in the normal derived HBL100, HBR SVI.6.1 and
184A1 but little or none in ZR-.75-1, MCF-7, T47D and MDA-MB-231. FGFR1 was present in most of these
but FGFR2 was absent from T47D, MDA-MB-231 and HBL100. ZR-75-1 cells had a marked preponderance
of FGFRI variants lacking part of the coding sequence.
Aberrant receptor processing may provide clues concerning the role of FGF's and their potential involve-
ment in malignancy.
The fibroblast growth factors (FGF), acidic FGF, basic
FGF, int-2, hst/k-FGF, FGF 5, FGF 6 and keratinocyte
growth factor (Klagsburn et al., 1986; Gospodarowicz et al.,
1986; Dickson & Peters, 1987; Tiara et al., 1987; Delli Bovi
et al., 1987; Zhan et al., 1988; Rubin et al., 1989; Marics et
al., 1989) are a group of structurally related heparin binding
polypeptide mitogens of widespread tissue distribution that
induce proliferation of most cultured cells derived from
embryonic mesoderm and neuroectoderm, including endo-
thelial cells. Sharing 33-55% amino acid sequence identity
and similar genomic organisation, they are involved in
differentiation, embryogenesis, angiogenesis, chemotaxis and
wound healing (Baird et al., 1987; Burgess & Maciag, 1989;
Rifkin & Moscatelli, 1989; Maxwell et al., 1991).
The hst and int-2 genes are co-amplified in a minority of
human cancers, including breast (Theillet et al., 1989) but are
poorly expressed. Acidic FGF expression is largely confined
to neural tissues (Maxwell et al., 1991) whereas bFGF is
ubiquitously distributed in normal human tissues (Cordon-
Cardo et al., 1990), and in neural and squamous carcinomas,
melanomas, osteosarcomas and hemangiomas (Takahashi et
al., 1990; Shulze-Osthoff et al., 1990). It is mitogenic for
cultured mammary epithelial cells (Takahashi et al., 1989;
Briozzo et al., 1991) and stimulates plasminogen activator
(Lopez et al., 1986) which has been implicated in tumour
invasion (Moscatelli & Rifkin, 1988). Basic FGF has been
immunolocalised in myoepithelial cells in benign breast and
around intraduct carcinomas but was not detected in cancer
cells (Gomm et al., 1991).
The cellular response to these peptides is mediated through
cell surface receptors composed of several extracellular
immunoglobulin-like domains, a transmembrane region and
an intracellular portion exhibiting intrinsic tyrosine kinase
activity (Ruta et al., 1988; 1989; Lee et al., 1989; Safran et
al., 1990). Several distinct human genes named fig (FGFR1),
bek (FGFR2), FGFR3 and K-sam (also FGFR2) bearing
sequence homology to the chick FGF receptor gene (Lee et
al., 1989) have been described (Dionne et al., 1990; Keegan et
at, 11991 fattori et al., 1990). A fourth gene termed FGFR4
hi also been reported (Partanen et al., 1991). For the
FO;FRI (Fujita et al., 1991) and probably also the FGFR2
(Dionne et al., 1990), multiple forms of the receptor have
been found comprising deletions within the extracellular
domain, apparently generated by alternatively spliced
mRNA's. Variant forms of the murine receptor appear to be
developmentally regulated in neuroepithelium (Reid et al.,
1990).
In view of the diversity of action of the FGF peptides and
the apparent complexity in the processing of receptor iso-
forms, there is considerable potential for their involvement in
malignant transformation, as well as in normal cellular inter-
actions. In this report we describe the results of a study
designed to assess the expression of bFGF and of the
FGFR1 and FGFR2 receptors in human breast tissues. We
have compared the levels of these mRNA's in normal/benign
and cancerous biopsies with cultured cell lines and a variety
of normal human tissues. Our findings indicate widespread
expression of bFGF, FGFRI and FGFR2, and suggest that
many of these tissues contain variant FGFR1 receptor
mRNA's in differing ratios.
Materials and methods
Chemicals
32P dCTP (3000 Ci mmol ') was obtained from Amersham
(UK), random hexamers, pdN6, and dNTP's were from Phar-
macia (Uppsala), MMLV reverse transcriptase was from
GIBCO BRL (Pailsey, UK) and Taq polymerase was from
Penninsula Laboratories (UK). Tissue culture media and
foetal calf serum were from GIBCO (Paisley, UK). All other
reagents were obtained from Sigma (Dorset, UK) unless
indicated and were of the highest available grade.
Tissue samples
Normal, benign and malignant breast biopsies were obtained
from patients attending the Breast Clinics at St George's, the
Royal Marsden and allied hospitals in London. No treatment
had been given prior to surgery. Following histological con-
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firmation of diagnosis, samples were dissected for material of
interest and snap frozen and stored in liquid nitrogen.
Tissues were examined from 66 primary carcinomas from
patients aged between 29 and 79 years. Details of these
patients are given in Table I. The non-malignant samples
were composed of tissue removed from adjacent to cancer or
from benign tumour. Other tissues used in this study were
either surgical biopsy specimens or autopsy material.
Probes
The following cDNA inserts were used in this study: bFGF,
0.475 Kb excised from PBR322 (Abraham et al., 1986)
FGFR1, 1.2 Kb excised from pGEMl (Ruta et al., 1988) and
FGFR2 excised from pGEMl (Dionne et al., 1990). Hybri-
disations were initially performed using these clones, but
after the identity of the PCR products had been indepen-
dently verified (i.e. by restriction enzyme anaylsis), we used
PCR products for labelling.
Cell culture
The following breast cell lines (Engel & Young, 1978) were
maintained in continuous culture in Dulbecco's minimal
essential medium containing 10% foetal calf serum: MCF-7
(Michigan Cancer Foundation USA), T47D (Dr H. Freake),
ZR-75-1 (Dr M. Lippman) MDA-MB-231 (Mason Research
Institute, Rockville, MD, USA), HBR SV1.6.1 (Dr M.
O'Hare), and HBL100. Cell pellets of 184A1 and 184B5
breast lines (Stampfer & Bartley, 1985) were provided by Dr
M. Stampfer. The gastric line, KATO 111, was from Dr T.
Motoyama and was maintained in RPMI-1640 medium con-
taining 10% foetal calf serum. Cell pellets from squamous
carcinoma lines, SMN, GEE and PAP were obtained from
Dr B. Gusterson. The rhabdomyosarcoma cell line, A204,
was from Dr C. Cooper.
RNA isolation
Total cellular RNA was extracted from frozen tissue using
the guanidinium isothiocyanate procedure (Chirgwin et al.,
1979), and a modified technique (Chomczynski & Saatchi,
Table I Details of patients studied
Characteristic No. %
Total no. 66
Age range 29-79
Mean age 65
Menopausal status
pre 15 31
post 33 69
not known 18
T stage
TO 2 4
T, 15 33
T2 20 43
T3 6 13
T4 3 7
not known 20
Histological node status
negative 30 68
positive 14 32
not known 22
ER status
positive 17 61
negative 11 39
not known 38
Pathological size (mm)
10-20 21 55
>20 17 45
not known 28
Histological type
infiltrating ductal 36 90
infiltrating lobular 4 10
other 4
not known 22
1987) utilising RNAZOL (Biogenesis, Bournemouth, UK)
was used for cell lines. For Northern analysis, glyoxal-
denatured RNA was electrophoresed on 1% agarose, trans-
ferred to Hybond N membrane and hybridised with random
primer labelled (Feinberg & Vogelstein, 1983) cDNA.
Reverse transcription
First strand cDNA was synthesised using MMLV reverse
transcriptase. RNA (2jig in 12Al) was boiled, snap cooled
and added to 1 p1 of enzyme (200 units), 4p1 5 x reaction
buffer (250 mM Tris-HCl, pH 8.3, 375 mM KC1, 15 mM
MgCl2), 1 p11 dNTP (20 mM each dATP, dCTP, dGTP and
dTTP), 1 ftl dithiothreitol and 1,utl random hexamers (250
ng). Following incubation at 37-42° for 1 h, the mixture was
heated to 950, snap cooled and stored at - 20°C. With each
experiment an additional tube which contained all the re-
agents except the enzyme was always included as a blank
control.
Polymerase chain reaction amplification
Specific cDNA sequences were amplified (Saiki et at., 1988)
in a reaction mix (100 .lI) composed of 1-4 JLl cDNA (equi-
valent to 100-400 ng RNA), 2 units Taq polymerase, 200tLM
dNTP, 200 ng each of the 5' and 3' sequence specific primers
in various combinations and buffer containing (in final con-
centrations) 8 mM Tris-HCl pH 8.4, 40 mM KCI, 1.5 mM
MgCl2 and 0.02% Tween, and overlaid with mineral oil. In
the standard procedure, 18 cycles of amplification were per-
formed with denaturation for 30 s at 94°, annealing for 1 min
at 45° and extension at 72° for 1 min with an extra 9 min
extension for the last cycle. An aliquot (25 1l) was removed
for measurement of GAP and the reaction continued for a
further 12 or 22 cycles using the same parameters for the
other gene products. All samples were analysed on at least
two separate occasions to check for reproducibility. If there
was more than 20% variation samples were re-done.
In preliminary experiments to establish the conditions
under which the levels in individual samples could be com-
pared, the input cDNA was varied from 3-200 ng, and cycle
number from 4-40.
Gel electrophoresis, blotting andhybridisation
Aliquots of chloroform extracted PCR products (10ttl) were
electrophoresed in 1.5% agarose in Tris acetate EDTA buffer
pH 8 containing ethidium bromide. Care was taken to ensure
that exact amounts were loaded, this being essential for
quantitative comparisons.
For blotting, gels were soaked briefly in 0.4 M NaOH, and
DNA transferred onto Hybond N+ membrane in the same
buffer. For hybridisation, filters were placed in roller bottles
(Hybaid, UK) with a solution (60p1lcm2) containing 50%
(v/v) formamide, 0.1% SDS, 5 x Denhardts (0.1% each of
polyvinylpyrrolidine, bovine serum albumin and ficoll), 5 mM
EDTA, 75 mM NaCl and 250,sg ml-' denatured sonicated
salmon sperm DNA, and incubated at 420 for 4-6 h. After
this time, the relevant probe (either cDNA or PCR product)
labelled with 32P-dCTP (to specific activities between 5.108 to
I09 c.p.m. tg-' DNA) using the random primer method
(Feinberg & Vogelstein, 1983) was added and incubation
continued for a further 16-20h. Filters were subsequently
washed in 2 x SSC, 0.1% SDS at 20°C for 25 min with five
changes of buffer, and then at 60-65°C in 0.1 x SSC, 0.1%
SDS for 1 h, with two changes of buffer, and exposed to
Amersham hyperfilm at - 70°C using intensifying screens for
periods between 30 min to several days. Band intensities were
quantified using a laser densitometer.
Calculation ofresults
To compare the levels of expression of the bFGF, FGFR1
and FGFR2 genes in different samples, the densitometric
readings were expressed as a ratio of the signal obtained forBASIC FGF, FGFR1 AND FGFR2 IN HUMAN BREAST 275
GAP, a ubiquitously expressed gene encoding a common
glycolytic enzyme. These values were normalised against the
value obtained for A204 (for bFGF and FGFR1) or KATO
111 (for FGFR2) cells, a sample of which was included on
every run and was present on each blot. The final value was
calculated as below:
Signal for FGFR (sample). x signal for FGFR (A204).*
signal for GAP (sample). signal for GAP (A204).
* or KATO 111 as appropriate.
Statistical tests
In order to compare the two unequal groups of cancer and
non-malignant tissues, both with skewed distributions, we
used a non-parametric test, the Mann Whitney U test, which
gave a two tailed probability. The data was also analysed by
the Kruskal-Wallis one-way analysis of variance by ranks
and gave the same probability values.
TRANSMEMBRANE REGION
EXTRA-CELLULAR REGION INTRA-CELLULAR REGION
Figure 1 Schematic representation of the functional domains of
the FGFR to show the approximate areas included in the RNA
coding sequence amplified by the FGFR primers used in this
study.
Restriction enzyme analysis
To verify identity of PCR products, a sample was ethanol
precipitated following a phenol extraction, resuspended in
water and digested for 3 h with the appropriate restriction
enzyme. An aliquot was electrophoresed on 1% agarose and
bands visualised with ethidium bromide.
Oligonucleotide primers
Oligonucleotides were synthesised on a Cyclone Plus DNA
Synthesiser (Milligan Bioresearch, Massachusetts, USA) by
phosphoramidite chemistry, deprotected by treatment with
NH40H for 5-6 h at 55°C, vacuum dried, resuspended in
water and used without further purification.
The primer pairs (Table II) were designed such that the
intervening sequence contained at least one intron. The func-
tional domains of the FGFR's encoding the regions amplified
are shown in Figure 1.
Results
We were unable to detect the presence of mRNA for either
FGFR1 or FGFR2 using conventional Northern blotting
methods, with up to 20 ig of total RNA extracted from
breast tissues, under conditions in which the appropriate
bands could be seen with A204 or KATO 111 cells. Use of
poly A' RNA could increase sensitivity, but tumour tissues
generally yielded too little RNA for poly A' selection. We
therefore used the PCR technique to perform this study.
Optimisation ofPCR conditions
Figure 2 (inset) shows the accumulation of GAP PCR prod-
uct with varying number of amplification cycles, using an
input of 100 ng of RT product from the RNA of a tumour
sample taken at random. Whilst ethidium bromide stained
bands were visible after 20 cycles, product was detected after
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Figure 2 GAP PCR products, accumulated from 3-200 ng RT
product from a random breast tumour sample after 18 cycles of
amplification, were electrophoresed in 1.5% agarose, blotted onto
Hybond N+ membrane and hybridised with 32P-labelled GAP
cDNA. Autoradiographic signals obtained following exposure to
Hyperfilm were quantified using laser densitometry. Similar
results were obtained with two other samples. Inset shows
accumulation of GAP PCR product with increasing number of
amplification cycles using lOOng RT product synthesised from
the RNA of a randomly selected breast tumour sample. The
arrow indicates the approximate mid range of the linear part of
the curve. These results were reproduced using at least four other
samples, on separate occasions.
12 cycles by hybridisation with 32P-labelled GAP cDNA, and
increased linearly between 10-30 cycles. The mid-range, 18
cycles, was therefore selected for measuring GAP levels.
Product accumulation was directly proportional to input
template (3-200 ng RNA) after 18 cycles (Figure 2). The
reproducibility of the method was assessed in several experi-
ments in which the RT product from 2 jig RNA from 13
Table II Oligonucleotide primers
Product size
RNA Primer sequence (bp) Reference
bFGF CTGTACTGCAAAAACGGG 349 Abraham et al., 1986
AAAGTATAGCTTTCTGCC
FGFR1 (A) CCTCTTCTGGGCTGTGCT 433 Dionne et al., 1991
CGGGCATACGGTTTGGTT
FGFR1 (B) GACAAAGAGATGGAGGTGCT 801 Dionne et al., 1991
GTTGTAGCAGTATTCCAGCC
FGFR2 GGTCGTTTCATCTGCCTGGT 578 Dionne et al., 1991
CCTTCCCGTTTTTCAGCCAC
GAP TCCCATCACCATCTTCCA 379 Arcari et al., 1984
CATCACGCCACAGT1--TCC
FGFR2
FGFRl A
FGFR1 B
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Figure 3 Southern blot showing GAP PCR products. To evaluate the reproducibility of the PCR technique, RT products
(equivalent of 100 ng), from 21tg of 13 breast tumour RNA samples, were amplified through 18 cycles of PCR using GAP primers
alone a, or in the presence of either FGFR1 B primers b, or of FGFR1 A and FGFR2 primers c. Aliquots were electrophoresed
through 1.5% agarose, blotted only Hybond N+ membrane and hybridised with 32P-labelled GAP cDNA. Samples from a and b
were run on the same gel and all three were hybridised and exposed to Hyperfilm together to achieve identical conditions. Control
samples run in lanes marked with an asterisk, were from PCR reactions using RNA from mock RT reactions in which the reverse
transcriptase had been ommitted.
samples was divided into three portions and GAP amplified
(a), alone (b), in the presence of FGFR1 primers B or (c), in
the presence of FGFR1 A and FGFR2 primers (Figure 4):
the variation was generally no greater than 50%, and the
yield of GAP product was not greatly affected by the
presence of the other primers. The yield of product from the
FGFR1 and FGFR2 primers was reduced when GAP
primers were present; but independently of template. The
bFGF primers would only work on their own. Thus the
optimal primer combinations used were (a), GAP and
FGFR1 B (b), GAP and FGFR1 A and FGFR2 and (c),
bFGF alone. In the latter case it was necessary to amplify
the GAP control separately, but to maximise uniformity,
complete double volume PCR mixes containing cDNA were
divided into two tubes containing the respective primers, and
amplification performed in adjacent wells of the Thermo-
cycler. Forty cycles of PCR were optimal for detection of
FGFR1 and FGFR2 and 30 cycles were most suitable for
bFGF (Figure 4), being within the linear stage of
amplification. The slope of the linear part of the curve for
each primer set was very similar, suggesting similar
amplification efficiencies under the particular conditions we
used. It should also be noted that this linear amplification
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Figure 4 Accumulation of PCR products using bFGF (0),
FGFR1 A (0), FGFR1 B (0) and FGFR2 (U) primers, in the
combinations described in Methods, with aliquots (100 ng) of RT
product from random tumour samples amplifed through 55
cycles. Equal aliquots, removed after indicated number of cycles,
were electrophoresed through 1.5% agarose, blotted onto
Hybond N+ membrane and hybridised with the appropriate 32p_
labelled probe. Exposure to Hyperfilm was carried out at - 70°C
and autoradiographic signals quantified by laser densitometry.
Data are from one of two such experiments showing similar
results.
was occurring at a time when GAP amplification had
plateaued after 30 cycles, in the same reaction mixture. Thus
it is valid to sample different PCR products at different cycle
numbers.
For all the genes concerned we verified the identity of the
product both by demonstrating hybridisation to the appro-
priate cDNA and by site specific cleavage with restriction
enzymes (data not shown).
Expression ofbFGF in breast tissues
All 66 biopsies taken from patients with primary breast
cancer, and 28 samples of either histologically normal tissue
taken from adjacent to cancer or from patients with benign
disease produced the expected 349 bp bFGF PCR product
but the relative amounts varied greatly within both groups
(Figure 5). The mean ± s.e.m. for the cancers was 0.87 ± 0.12
as compared with 4.25 ± 1.03 for the non-malignant group;
these being significantly different (P<0.0001).
Expression ofFGFR2 in breast tissues
As with bFGF the individual levels of FGFR2 PCR product
varied considerably in both cancers and non-malignant tis-
sues alike (Figure 5). Apart from the expected 578 bp frag-
ment, hybridisation to two smaller bands was also observed;
the origin of these is being investigated in the light of data
which has appeared since this work was completed (Hou et
al., 1991). Only in three samples of cancer (<5%) was
FGFR2 undetectable. Otherwise, there was a significantly
greater level of amplified FGFR mRNA product in the
normal tissues: means ± s.e.m. being 3.42 ± 0.46 and 9.92 ±
2.5 for cancers (n = 66) and non-malignant (n = 31) samples
respectively (two-tailed probability = 0.0078).
Expression ofFGFRI in breast tissues
We used two sets of primers to amplify either the region
encoding the outermost immunoglobulin-like domain, or that
spanning the sequence from the third immunoglobulin-like
domain to, and including, half of the tyrosine kinase domain.
Again a wide range of values were recorded for both cancers
and non-malignant biopsies, with both pairs of primers
(Figure 5). With FGFRI B primers the two groups had
means ± s.e.m. respectively of 0.97 ± 0.11 (n = 66) and
1.78 ± 0.39 which were not significantly different. Product
was obtained with all samples. With FGFR1 A primers the
means ± s.e.m. were 3.96 ± 0.62 (n = 66) and 12.6 ± 2.6
(n = 31) for cancers and non-malignant groups respectively.BASIC FGF, FGFRI AND FGFR2 IN HUMAN BREAST 277
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Figure 5 Scattergrams showing the relative amounts of PCR
product accumulated after amplification of RT product (cal-
culated as described in Methods) from cancer or non-malignant
breast biospies. For bFGF the mean values of 0.87±0.12 (s.e.m.)
and 4.25 ± 1.03 respectively, were significantly different
(P<0.0001). For FGFR2, the two groups had mean values of
3.42 ±0.46 (s.e.m.) and 9.92 ±2.5 respectively, which were
significantly different (P =0.0078). For FGFRI there was no
difference between the two groups (means of 0.97±0.11 (s.e.m.)
and 1.78±0.39 respectively) when primers B were used. With
primers A, the mean values of the two groups (3.96 ±0.62 (s.e.m.)
and 12.6±2.6 respectively) were significantly different
(P = 0.0002).
These two values were significantly different (two-tailed pro-
bability = 0.0002). In the cancers, two samples (<3%) had
no detectable FGFR1 A product and three in the non-
malignant group (10%). The relative amount of FGFR1
product varied considerably depending upon which region
was being amplified. Thus, instead of the expected constant
ratio for FGFRI A: FGFR1 B product for all samples, we
obtained widely different ratios. The mean values of the
cancer and non-malignant groups were significantly different
(means ± s.e.m. were 8.7 ± 1.5 (n = 63) and 46.9 ± 25 (n =
27) (two-tailed probability = 0.046).
Relationship ofbFGF, FGFRI and FGFR2 expression to
clinical parameters
For those patients for whom clinical data was available, we
analysed the results with respect to the major clinical
features; T stage, nodal involvement and oestrogen receptor
status. Table III shows the breakdown of this analysis, which
was done by using a purely arbitary cut off point to divide
the tumour samples into two groups, with (comparatively)
high and low levels of expression. The numbers are still too
small to permit accurate correlate into clinical parameters,
but oestrogen receptor positivity appeared to be associated
with high expression if the FGFR2 mRNA. However, due to
the small numbers, this relationship was only marginally
significant (P<0.06, Fishers exact two-sided probability).
Expression ofbFGF, FGFRI and FGFR2 in cell lines
We examined RNA from four cell lines derived from breast
cancer (ZR-75, T47D, MCF-7 and MDA-MB-231), four
derived from normal breast cells (HBLI0O, HBRSV1.6.1,
184A1 and 184B5) and three from squamous carcinomas
(GEE, PAP and SMN) (Figure 6). There was no bFGF
product in three of the breast cancer lines, and only a small
amount in ZR-75-1 cells. In contrast, all four of the 'normal-
derived' breast lines had levels comparable with the low-
range values found in cancer tissues. Of the three squamous
lines two gave detectable bFGF product.
The FGFR2 product was present in MCF-7 and in ZR-75-
1 cells but undetectable in T47D and HBLl0O cells. The
highest levels were seen in HBR SVI.6.1 and the 184B5 cells.
Only PAP of the squamous lines produced FGFR2. Using
FGFR1 A primers, highest levels were found in ZR-75 (in
the same range as cancer tissues) with lower levels in
HBL100, HBRSVI.6.1 and T47D. Product was barely detect-
able in MCF-7, and absent in 184B5 and 184A1. In the
squamous lines expression was observed in GEE and SMN
but not PAP cells. With the FGFR1 B primers, the pattern
was similar except that there were very low amounts for
ZR-75-1.
Expression ofbFGF, FGFRI and FGFR2 in a panel ofnormal
human tissues
Basic FGF was present in heart, ileum, colon, kidney,
stomach, adrenal gland, ovary, skin and thyroid with less
than 5 fold differences between them, except for lung, which
was much higher. The FGFR2 gene was also ubiquitously
expressed, except in heart. The highest amount was present in
the thyroid specimen.
All samples expressed FGFR1 with highest levels in skin
ovary, and heart (Figure 7).
Table III Relationship between bFGF, FGFR1 and FGFR2 PCR product levels and
clinical status
Relative level Total no. Stage Nodes ER
RNA ofPCRprod. patients TOIT2 T3/T4 - + - +
bFGF <0.6 36 26 3 20 10 8 11
>0.6 29 16 6 16 7 4 8
FGFRI <3 39 24 4 19 11 9 8
(A) > 3 27 19 5 18 6 3 10
FGFR1 < 1 39 26 5 22 10 7 9
(B) > 1 27 17 4 16 7 5 10
FGFR2 <2 38 26 5 23 9 10 8
>2 28 17 4 14 8 2 11
A and B refer to the primers used. Note that details not available for all patients.
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Figure 6 Histograms showing the accumulation of PCR prod-
ucts from RT products of cell line RNA, for bFGF, FGFRI
(primers A), FGFR1 (primers B) and FGFR2 as indicated. Ex-
perimental details are described in Methods.
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Figure 7 Histograms showing the accumulation of PCR prod-
ucts from RT products of RNA extracted from various normal
human tissue samples, with bFGF, FGFRI (primers A and B)
and FGFR2 primers, as indicated. Experimental details as des-
cribed in Methods.
This study describes the expression of bFGF and two of the
four recently identified FGF receptors, FGFR1 and FGFR2
in a series of human breast biopsies, cell lines and in a panel
of normal tissues. Due to their low abundance, we devised a
sensitive PCR based protocol which relies on co-ampli-
fication of an internal ubiquitously expressed sequence, and
reference to values determined for an arbitary standard sam-
ple. An advantage of using GAP, is that the level of this gene
is likely to reflect the metabolic state of the cells and
therefore its fluctuations would correct for differences due
simply to differences in the proliferative activity, rather than
specifically malignancy associated events. This procedure,
similar to one described by Noonan et al. (1990) and unlike
methods in which exogenously added cRNA is used (e.g.
Wang et al. (1989)) overcomes the problems of variations in
RNA quality and purity, sampling errors, and other differ-
ences in electrophoresis, gel blotting, hybridisation and auto-
radiographic exposure times. The main limitation is that our
values are purely arbitary and the actual levels of the three
genes cannot be compared with each other. Although bFGF
had to be amplified separately from GAP, we ensured that
buffer conditions were identical and both tubes had exactly
the same amount of cDNA. Duplicates done in this way
showed no more than 20% variation.
In apparent contrast with earlier immunohistochemical
observations (Gomm et al., 1991), we found that bFGF
mRNA was present in breast cancer as well as benign tissue,
though at significantly reduced levels. It is unclear whether
this reflects the difference in sensitivity of the two methods,
or differential translational control. All the breast cell lines
derived from normal epithelia expressed the gene whilst only
one of the four cancer derived lines did so and to a much
lesser extent (more than 50 fold less). Valverius et al. (1990)
reported the presence of bFGF mRNA in primary cultures of
human mammary fibroblasts, but not in the transformed
184A1N4 epithelial cells. This discrepancy is probably due to
the greater sensitivity of PCR over Northern blotting
methods. We are currently doing cellular localisation using a
combination of PCR with dissection of frozen tissue sections
(Luqmani et al., 1992) to determine the precise cellular origin
of the amplified RNA. The widespread presence of bFGF
(Cordon-Cardo et al. 1990) suggests an important role in
normal cellular function, but the lack of a signal peptide
(Jaye et al., 1986), precluding secretion in the classically
recognised manner, has posed problems regarding its poten-
tial as a locally produced para/autocrine factor. However its
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appearance in conditioned media (Sato & Rifkin, 1988; Rif-
kin, 1991) and its association with the extracellular matrix
(Saksela et al., 1988; Baird & Walicke, 1989) suggest that it
may be externalised in conjuction with glycosaminoglycans
which are also thought to modulate its biological activity
(Ruoslahti & Yamaguchi, 1991; Yayon et al., 1991).
Both FGFR1 and FGFR2 were expressed in all tissues
except heart (an observation also made by Kornbluth et al.
(1988) and Reid et al. (1990)) and in the vast majority of the
breast tissues. The wide range of values reflects the sensitivity
of the PCR. In the light ofgrowing evidence for the existence
of truncated FGFR isoforms generated by alternative splic-
ing, affecting all three structural domains, our results with
the FGFR1 primers suggest that these commonly co-exist in
the same tissue but in greatly varying proportions. Thus the
ratio of PCR products obtained using the two FGFR1
primer sets reflects a greater frequency of FGFR mRNA's
with deletions in the outermost Ig like domains in the cancer
tissues as compared with the non-malignant breast samples
but that the truncated form is present in both groups. Fujita
et al. (1991) observed this to be the major form in placenta
and found that it still mediated biologic response to both
acidic and bFGF, suggesting that this domain is not required
for binding but may play some other facilitatory role.
Another placental cDNA encoding a soluble form of the
placental receptor contains only the first two Ig like domains
has been expressed in CHO cells and shown to undergo
oligomerisation and retain binding activity (Duan et al.,
1991). A truncated FGFR2 cDNA encoding only the signal
peptide and the first Ig domain followed by a termination
codon, and an FGFR1 clone with only the two outer Ig like
regions have also been reported (Dionne et al., 1990). Spliced
variants for the K-SAM (FGFR2) receptor have also been
described in gastric carcinoma cells (Hattori et al., 1990). We
found not only differential expression of FGFR2 and
FGFR1 in the various cell lines studies, but also evidence of
forms of the FGFR1 with deletions. ZR-75-1 cells appeared
to have mRNA encoding only the external part. Hou et al.
(1991) postulate the existence of up to 12 different variants of
the FGFR1 receptor, which by extrapolation to the other
three identified FGF receptors could extend this family to 48
isoforms. Johnson et al. (1991) have also recently described a
number ofdifferent variants of FGFR1. The antisense primer
of the FGFR1 A pair used in this study covers a region in
which another variant involving a two amino acid deletion
has been found: thus, lack of product with this primer may
be due to such a variant in our samples, though it would
have to be a predominant form. In the light of these recent
findings, we are currently designing new primers to map these
regions.
Other receptors also appear to display variant types. For
example, developmentally regulated isoforms of the murine
retinoic acid receptor beta generated by alternative splicing
and differential promoter usage have also been described and
may reflect functional specificities (Zelent et al., 1991).
The presence of receptors on several breast cell lines has
been demonstrated by ligand binding studies (Peyrat et al.,
1991; Briozzo et al., 1991) and by Northern analysis, using
6fig mRNA, in MCF7 cells (Lehtola et al., 1992). Mitogenic
effects have been noted on both MCF-7 cells and on immor-
talised mammary epithelial cells derived from breast reduc-
tion mammoplaasty (Valverius et al., 1990). Primary
monolayer cultures of breast epithelial cells grown out of
fragmented biopsy tissue were reported to show a modest
response to bFGF (more pronounced in cancer than in non-
malignant samples) but were unaffected by aFGF (Takahashi
et al., 1989). As none of these studies were concerned with
the identity of the receptor, it is not yet clear which of the
sub-types are involved. Our results suggest that FGFR1
mediated events could be studied using T47D, MDA-MB-231
and HBLIOO lines, all of which appear to be FGFR2 nega-
tive. The FGFR1 negative squamous line, PAP, could be
used to study FGFR2 action. This of course does not take
into account the presence of FGFR3 and FGFR4, the ex-
pression of which has yet to be determined.
A recent survey (Adnane et al., 1991) of 387 breast car-
cinomas showed amplification of both the FGFR1 and
FGFR2 genes in about 12% of cases: FGFR1 amplification
was correlated with nodal metastases and amplification of the
HST, Int 2 and BCL I genes, and FGFR2 with c-myc.
This work was supported by the Cancer Research Campaign. We
thank Caroline Mortimer for help with the clinical data.
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